Platelet rich plasma (PRP) is a portion of the plasma fraction of analogous blood, which contains platelet concentration more than standard concentration. Platelets contains bio proteins that helps in healing, tissue regeneration, and blood loss. Platelet rich plasma protein consists of three proteins, which acts as cell adhesive molecules that are fibrin, fibronectin, and vitronectin. PRP therapy can improve joint and trauma-related wound healing. The surgery can improve other aesthetic surgeries, treat male pattern baldness, and encourage the growth of hair transplants.
To promote the repair of injured tendons, ligaments, muscles, and joints, platelet-rich plasma (PRP) therapy involves injections of a patient's own concentrated platelets. PRP injections work to treat musculoskeletal issues by enhancing each patient's natural healing process. One to several tubes of your own blood are used to prepare PRP injections, which is done by centrifuging the blood to concentrate the platelets. The damaged or ill body tissue is subsequently given an injection of these activated platelets. This causes the release of growth factors, which promote and boost your body's production of reparative cells.
Market Dynamics
Evolving role of platelet rich plasma in plastic surgeries for facial rejuvenation and hair restoration is expected to drive the global platelet rich plasma market over the forecast period. For instance, on January 1, 2021, an article published in national library of medicine stated that there is a strong proof using unbiased measurement techniques that shows successful treatment results for skin rejuvenation, hair development, wound healing, and fat graft take. There is a therapeutic benefit to using plasma rich in platelets as a unique treatment method for alopecia and skin rejuvenation.
Key features of the study:
- This report provides in-depth analysis of the global platelet rich plasma market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global platelet rich plasma market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Arthrex, Inc., Stryker Corporation, Johnson and Johnsons Ltd., Zimmer Biomet Holdings Inc., Terumo Corporation, Glofinn Oy, Medira Ltd., Regen Lab S.A., CollPlant, Generex Biotechnology Corporation, Estar Technologies Ltd., Dr. PRP America, Cesca Therapeutics, Inc., Arteriocyte Medical Systems, Harvest Technologies Corp.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global platelet rich plasma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global platelet rich plasma market
Detailed Segmentation:
- Global Platelet Rich Plasma Market, By Type:
- Pure PRP
- Leukocyte rich PRP
- Pure PRF
- Leukocyte rich PRF
- Global Platelet Rich Plasma Market, By Origin:
- Autologous
- Allogenic
- Homologues
- Global Platelet Rich Plasma Market, By Application:
- Neurosurgery
- Cosmetic Surgery
- Orthopedic Surgery
- General Surgery
- Others
- Global Platelet Rich Plasma Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Arthrex, Inc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Stryker Corporation
- Johnson and Johnsons Ltd.
- Zimmer Biomet Holdings Inc.
- Terumo Corporation
- Glofinn Oy
- Medira Ltd.
- Regen Lab S.A.
- CollPlant
- Generex Biotechnology Corporation
- Estar Technologies Ltd.
- PRP America
- Cesca Therapeutics, Inc.
- Arteriocyte Medical Systems
- Harvest Technologies Corp.
"*" marked represents similar segmentation in other categories in the respective section.